Antonella Castagna

Languages:
EN
FR
IT

Biography

Professor Antonella Castagna is the head of the Unit of Infectious Diseases at IRCCS Ospedale San Raffaele in Milan, based in San Raffaele Turro, and Director of the School of Specialization in Infectious and Tropical Diseases at the University Vita-Salute San Raffaele in Milan.  

Her education began with a Degree in Medicine and Surgery at the University of Milan in 1985. In 1989, she obtained specialization in Infectious Diseases at the same University. She also had periods of specialization abroad: from 1985 to 1987, she was a Fellow in Neurovirology at the Neurovirology Department (University of Chicago, USA); in 1990, she was a Research Associate at the National Bacteriological Laboratory Hospital, Karolinska Institute (Stockholm, Sweden).

Prof. Castagna has extensive knowledge of infectious diseases, particularly those of viral etiology, including HIV and SARS-CoV-2 infection.

Since 1992, he has worked as a physician and activity area coordinator at Ospedale San Raffaele.

From 2014 to 2019, she was the Clinical Group Leader of the Unit of Management and Antiretroviral Therapy of HIV Infection, IRCCS Ospedale San Raffaele.

Since 2017, she has been National Coordinator of the Prestige Registry (www.registroprestigio.com) focused on the study of patients with HIV infection and extensive antiretroviral drug resistance. Since 2017, she is also the head of the CSLHIV Cohort, an observational, longitudinal clinical database enrolling adult patients with infectious diseases (HIV infection, hepatitis, tuberculosis and other infections) maintained at the Infectious Diseases Unit of IRCCS Ospedale San Raffaele since 1991.

Since 2020, she is responsible for the computerized collection of epidemiological, clinical and therapeutic information of hospitalized patients diagnosed with SARS-CoV-2 infection within the Covid-BioB project of IRCCS San Raffaele.

She is Principal Investigator of several national and international observational studies and prospective randomized trials.

She is Member of the steering committee of several national and international networks (ICONA; EUROSIDA, COHERE, RESPOND, STIPNET) and, since 2019, she is Chair of the Panel for the drafting of the Italian Guidelines on the use of Antiretroviral Therapy and the diagnostic-clinical management of people with HIV-1 infection; since 2021, she is member of the Governing Body of EACS (European AIDS Clinical Society).

She is the author of numerous book chapters and over 500 publications in prestigious scientific journals. Her H-index is 51.

Read moreRead less

Do you need an appointment?

Contact us and we will take care of you.

Publications

Latest publications

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
N Engl J Med. 2020; 382(13):1232-1243
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team.
Compassionate Use of Remdesivir for Patients with Severe Covid-19
N Engl J Med. 2020;382(24):2327- 2336
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinus
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial
JAMA, 2020;324(11):1048-1057
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail 45 MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators.
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain
J Clin Invest. 2020;130(12):6366-6378
Secchi M, Bazzigaluppi E, Brigatti C, Marzinotto I, Tresoldi C, Rovere-Querini P, Poli A, Castagna A, Scarlatti G, Zangrillo A, Ciceri F, Piemonti L, Lampasona V.
Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)
.J Antimicrob Chemother. 2019 ;74(7):2039-2046.
Castagna A, Muccini C, Galli L, Bigoloni A, Poli A, Spagnuolo V, Nozza S,Racca S, Galli A, Cinque P, Carini E, Lazzarin A.
Stepping up HIV-1 low-level viraemia surveillance in South Africa
Lancet Infect Dis. 2018; 18(2):130-131. doi: 10.1016/S1473-3099(17)30680-1.
Castagna A, Galli L.
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus
J Antimicrob Chemother. 2018 ;73(1):177-182.
Castagna A, Ferrara M, Galli L, Comi L, Sterrantino G, Cenderello G, Zaccarelli M, Focà E, Roncadori A, Lazzarin A; PRESTIGIO Study Group.
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial
Lancet HIV 2015 ;2(11):e464-73
Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, Raffi F, Arribas JR; NEAT001/ANRS143 Study Group.
MODAt Study Group. Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results
AIDS. 2014 ;28(15):2269-79
Castagna A, Spagnuolo V, Galli L, Vinci C, Nozza S, Carini E, D'Arminio Monforte A, Montella F, Antinori A, Di Biagio A, Rusconi S, Lazzarin A;
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravirresistant HIV-1: 24-week results of the phase III VIKING-3 study
J Infect Dis. 2014 ;210(3):354-62
Castagna A, Maggiolo F, Penco G, Wright D, Mills A, Grossberg R, Molina JM,Chas J, Durant J, Moreno S, Doroana M, Ait-Khaled M, Huang J, Min S, Song I, Vavro C, Nichols G, Yeo JM; VIKING-3 Study Group.

Do you need an appointment?

Contact us and we will take care of you.